CRISPR Therapeutics AG Quarterly Depreciation in USD from Q3 2015 to Q3 2024

Taxonomy & unit: us-gaap: USD
Description: The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
Summary: CRISPR Therapeutics AG quarterly/annual Depreciation history and growth rate from Q3 2015 to Q3 2024.
CRISPR Therapeutics AG Depreciation for the quarter ending September 30, 2024 was $4.8M, a 2.04% decline year-over-year.
CRISPR Therapeutics AG Depreciation for the twelve months ending September 30, 2024 was $19.3M, a 6.76% decline year-over-year.
CRISPR Therapeutics AG annual Depreciation for 2023 was $19.8M, a 17.8% decline from 2022.
CRISPR Therapeutics AG annual Depreciation for 2022 was $24.1M, a 34.6% increase from 2021.
CRISPR Therapeutics AG annual Depreciation for 2021 was $17.9M, a 96.7% increase from 2020.

Depreciation, Trailing 12 Months (USD)

Depreciation, Quarterly (USD)

Depreciation, YoY Quarterly Growth (%)

Period	TTM Value	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed
Q3 2024	$19.3M	$4.8M	-$100K	-2.04%	Jul 1, 2024	Sep 30, 2024	10-Q	2024-11-05
Q2 2024	$19.4M	$4.8M	-$200K	-4%	Apr 1, 2024	Jun 30, 2024	10-Q	2024-08-05
Q1 2024	$19.6M	$4.8M	-$200K	-4%	Jan 1, 2024	Mar 31, 2024	10-Q	2024-05-08
Q4 2023	$19.8M	$4.9M	-$900K	-15.5%	Oct 1, 2023	Dec 31, 2023	10-K	2024-02-21
Q3 2023	$20.7M	$4.9M	-$100K	-2%	Jul 1, 2023	Sep 30, 2023	10-Q	2024-11-05
Q2 2023	$20.8M	$5M	-$2.3M	-31.5%	Apr 1, 2023	Jun 30, 2023	10-Q	2024-08-05
Q1 2023	$23.1M	$5M	-$1M	-16.7%	Jan 1, 2023	Mar 31, 2023	10-Q	2024-05-08
Q4 2022	$24.1M	$5.8M	-$500K	-7.94%	Oct 1, 2022	Dec 31, 2022	10-K	2024-02-21
Q3 2022	$24.6M	$5M	-$300K	-5.66%	Jul 1, 2022	Sep 30, 2022	10-Q	2023-11-06
Q2 2022	$24.9M	$7.3M	+$3.7M	+103%	Apr 1, 2022	Jun 30, 2022	10-Q	2023-08-07
Q1 2022	$21.2M	$6M	+$3.3M	+122%	Jan 1, 2022	Mar 31, 2022	10-Q	2023-05-08
Q4 2021	$17.9M	$6.3M	+$3.8M	+152%	Oct 1, 2021	Dec 31, 2021	10-K	2024-02-21
Q3 2021	$14.1M	$5.3M	+$3M	+130%	Jul 1, 2021	Sep 30, 2021	10-Q	2022-11-01
Q2 2021	$11.1M	$3.6M	+$1.4M	+63.6%	Apr 1, 2021	Jun 30, 2021	10-Q	2022-08-08
Q1 2021	$9.7M	$2.7M	+$600K	+28.6%	Jan 1, 2021	Mar 31, 2021	10-Q	2022-05-09
Q4 2020	$9.1M	$2.5M	+$1.1M	+78.6%	Oct 1, 2020	Dec 31, 2020	10-K	2023-02-21
Q3 2020	$8M	$2.3M	+$1M	+76.9%	Jul 1, 2020	Sep 30, 2020	10-Q	2021-11-03
Q2 2020	$7M	$2.2M	+$1.2M	+120%	Apr 1, 2020	Jun 30, 2020	10-Q	2021-07-29
Q1 2020	$5.8M	$2.1M	+$1.1M	+110%	Jan 1, 2020	Mar 31, 2020	10-Q	2021-04-27
Q4 2019	$4.7M	$1.4M	+$400K	+40%	Oct 1, 2019	Dec 31, 2019	10-K	2022-02-15
Q3 2019	$4.3M	$1.3M	+$500K	+62.5%	Jul 1, 2019	Sep 30, 2019	10-Q	2020-10-28
Q2 2019	$3.8M	$1M	+$100K	+11.1%	Apr 1, 2019	Jun 30, 2019	10-Q	2020-07-27
Q1 2019	$3.7M	$1M	+$200K	+25%	Jan 1, 2019	Mar 31, 2019	10-Q	2020-04-28
Q4 2018	$3.5M	$1M	+$200K	+25%	Oct 1, 2018	Dec 31, 2018	10-K	2021-02-16
Q3 2018	$3.3M	$800K	$0	0%	Jul 1, 2018	Sep 30, 2018	10-Q	2019-10-28
Q2 2018	$3.3M	$900K	+$200K	+28.6%	Apr 1, 2018	Jun 30, 2018	10-Q	2019-07-29
Q1 2018	$3.1M	$800K	+$100K	+14.3%	Jan 1, 2018	Mar 31, 2018	10-Q	2019-04-29
Q4 2017	$3M	$800K	+$300K	+60%	Oct 1, 2017	Dec 31, 2017	10-K	2020-02-12
Q3 2017	$2.7M	$800K	+$600K	+300%	Jul 1, 2017	Sep 30, 2017	10-Q	2018-11-07
Q2 2017	$2.1M	$700K	+$600K	+600%	Apr 1, 2017	Jun 30, 2017	10-Q	2018-08-07
Q1 2017	$1.5M	$700K	+$600K	+600%	Jan 1, 2017	Mar 31, 2017	10-Q	2018-05-08
Q4 2016	$900K	$500K			Oct 1, 2016	Dec 31, 2016	10-K	2019-02-25
Q3 2016		$200K	+$173K	+641%	Jul 1, 2016	Sep 30, 2016	10-Q	2017-11-08
Q2 2016		$100K			Apr 1, 2016	Jun 30, 2016	10-Q	2017-08-10
Q1 2016		$100K			Jan 1, 2016	Mar 31, 2016	10-Q	2017-05-11
Q3 2015		$27K			Jul 1, 2015	Sep 30, 2015	10-Q	2016-11-22

* An asterisk sign (*) next to the value indicates that the value is likely invalid.